-

Genetesis Announces Two Abstracts Selected for Presentations at Upcoming Scientific Meetings

MASON, Ohio--(BUSINESS WIRE)--Genetesis, a market leading biomagnetic imaging company, has announced that recent data collected in clinical study with the company’s lead product, CardioFlux was selected for abstract presentations at this year’s American College of Emergency Physicians (ACEP) Scientific Assembly later this month and at American Heart Association (AHA) Scientific Sessions in November. These presentations will discuss the utility and improvements to standard of care when using CardioFlux as a diagnostic imaging solution to detect myocardial ischemia and diagnose coronary artery disease. The CardioFlux Magnetocardiograph has been designated a FDA Breakthrough Device for its potential benefits in improving and optimizing care in the triage process.

American College of Emergency Physicians (ACEP) Research Forum:
Title: Detection of Acute Coronary Syndrome by Magnetocardiography
Date and Time: Tuesday, October 26, 2021 at 11:00 a.m. ET
Session Name: RF 18 Abstract Session: Cardiovascular (ACS and non-ACS)
Session Type: Oral Abstract Session
Presenter: Sharon Mace, MD, FACEP, FAAP, Principal Investigator of ACCMED, Emergency Medicine Physician at Cleveland Clinic
Abstract #: 1145

American Heart Association (AHA) Scientific Sessions:
Title: A Novel Way to Predict Obstructive Coronary Artery Disease Requiring Revascularization: The Use of Magnetocardiography
Date: Saturday, November 13 – Monday, November 15, 2021
Session Name: Health Tech Posters II
Session Type: Abstract Poster Presentation
Presenter: Nicholas Coriasso, DO, Cardiology Fellow (PGY5) at Ascension St. John Hospital
Abstract #: 10642

About Genetesis
Genetesis, Inc. is a medical imaging company focused on redefining the way myocardial ischemia and coronary artery disease are detected. By combining CardioFlux, our noninvasive biomagnetic imaging technology, with our proprietary cloud-based web services and machine-learning capabilities, we seek to become the standard of care for diagnosis of cardiovascular disease in the outpatient and acute care settings. Genetesis was founded in 2013 and is based in Mason, Ohio. For more information, visit https://genetesis.com/.

Contacts

Rhea Malhotra, 513-309-1440
Director, Product, rhea@genetesis.com

Industry:

Genetesis

Release Summary
Presentations will discuss improvements to standard of care when using CardioFlux to detect myocardial ischemia and diagnose coronary artery disease.
Release Versions
English

Contacts

Rhea Malhotra, 513-309-1440
Director, Product, rhea@genetesis.com

Social Media Profiles
Genetesis/Facebook
Genetesis/Instagram
Genetesis/LinkedIn
Genetesis/Twitter
More News From Genetesis

Genetesis Announces Formal Publication of Results from the MAGNETO Trial

MASON, Ohio--(BUSINESS WIRE)--Genetesis, Inc., a leader in the field of magnetocardiography (MCG), today announced that official results from its MAGNETO trial were published in a special issue of the American Heart Journal Plus: Cardiology Research and Practice. The results of MAGNETO demonstrate MCG’s ability to identify myocardial ischemia in low-to-intermediate risk patients presenting to the emergency department (ED) with acute chest pain and validate MCG’s performance compared to tests th...

Genetesis Receives 2nd FDA Breakthrough Device Designation for Non-Invasive Diagnosis of Myocardial Ischemia Using CardioFlux MCG

MASON, Ohio--(BUSINESS WIRE)--Genetesis, Inc., the leader in biomagnetic cardiac imaging solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device designation for its flagship imaging solution, CardioFlux MCG, to identify myocardial ischemia in patients who may be suffering from coronary microvascular disease (CMD). Historically, CMD has been hard to identify in clinical practice due to a lack of effective functional diagnostics with...

Genetesis Announces New Appointments to Executive Leadership Team

MASON, Ohio--(BUSINESS WIRE)--Genetesis, Inc., the leader in biomagnetic cardiac imaging solutions, today announced the appointment of three new members to the executive leadership team who will oversee and execute key aspects of commercialization and clinical research for its flagship solution, CardioFlux. This announcement comes in anticipation of market authorization from the FDA, which Genetesis expects to see later this year. “As we inch ever closer to the FDA granting our De Novo request,...
Back to Newsroom